Clinical Trial Update: Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ASLAN001 in combination with capecitabine in metastatic breast cancer patients who progressed on prior trastuzumab has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ASLAN001
• Capecitabine (capecitabine)

Snippet

Sponsor: ASLAN Pharmaceuticals | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED